IRB #

IRB00007397

Title

A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer

Principal Investigator

Gina Vaccaro

Study Purpose

The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (gemcitabine alone or with chemoradiation) with or without the addition of HyperAcute-Pancreas immunotherapy (the study drug) to find out which treatment is better.

Medical Condition(s)

Pancreas

Eligibility Criteria

Pancreas Cancer (Stage I or II)
No metastatic disease
Other previous cancer within 5 years

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

NewLink Genetics Corporation/Industry

Recruitment End

Compensation Provided

No